Log in or register to see all Alerts
New HTA Decisions in England
May 2021
Drug name
(selinexor)
Company
Karyopharm Therapeutics
Decision date
//
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and bone marrow cancers
Decision
Not recommended
Indication
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma in adults.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on selinexor with low-dose dexamethasone for treating refractory multiple myeloma in adults because the company did not provide an evidence submission. This is because Karyopharm Therapeutics has confirmed that it does not intend to make an evidence submission for the appraisal and will not be launching the technology in the UK. NICE will review this decision if the company decides to make a submission.